Patients with Classical Hodgkin Lymphoma with Less Than 10.5 CD20-Positive Reed–Sternberg Cells in 10 High-Power Fields Have Better Prognosis

• Published in: Indian journal of hematology & blood transfusion Vol. 38; no. 3; pp. 596 - 600
• Main Authors: Lacet, Dominique Fonseca Rodrigues, Oliveira, Cristiano Claudino
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01-07-2022; Springer Nature B.V
• Subjects: Blood Transfusion Medicine; Clinical outcomes; Hematology; Human Genetics; Immunohistochemistry; Lymphoma; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Pathophysiology; Short Communication; Immunohistochemistry; Patient outcome assessment; CD20 antigen; Hodgkin disease; Prognosis
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-021-01517-7

The CD20 immunoexpression in classical Hodgkin lymphoma (CHL) is variable and it may represent an intersection between the pathophysiology of CHL and the clinical prognosis of patients. Retrospective study with 174 patients with pathological diagnosis of CHL. Clinical data were reviewed from medical records. Immunophenotypic study with CD20 were performed in two ways: hotspot count and in 10 high-power fields (HPF). The data were tabulated and the
p
value less than 0.05 was considered significant. The CD20-positive phenotype was found in 45 (25.9%) of the total of 174 patients with available material. Patients with CD20 positivity on neoplastic cells tend to heal earlier, particularly those with less than 10.5 cells/10 HPF (
p
 = 0.037). Patients with CHL with less than 10.5 CD20-positive Reed-Sternberg cells in 10 HPF have better prognosis.